Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus after first-line sunitinib or pazopanib failure in metastatic renal cell carcinoma
2011-003416-23Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in renal cell carcinoma (RCC), sponsored by Novartis. Primary endpoint: Progression-free rate at 6 months. Started Dec 2011; status: completed.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2011-003416-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003416-23.